Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Rosenheck
Robert A
RA
Northeast Program Evaluation Center, Department of Veterans Affairs Connecticut Health Care System, West Haven, CT 06516, USA. robert.rosenheck@yale.edu
D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D006291:Health Policy / Q000191:economics; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000191:economics / Q000706:statistics & numerical data*; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States
D014150:Antipsychotic Agents